Wang Baoquan, Yang Lun, Qin Haiyun, Li Fengzhen, Zhang Peitong
Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China.
PLoS One. 2024 Aug 8;19(8):e0305070. doi: 10.1371/journal.pone.0305070. eCollection 2024.
KLKs have been proved to be key regulators of the tumor microenvironment. In this study, we explored the potential of Kallikrein-related peptidases (KLKs) as clinical diagnostic and prognostic markers in patients with kidney renal clear cell carcinoma (KIRC) as well as their relationship with common immuno-inhibitor and immune cell infiltration in the tumor microenvironment to provide new targets and novel ideas for KIRC therapy.
Oncomine, Gene Expression Profiling Interactive Analysis (GEPIA), UCSC Xena, Genotype-Tissue Expression (GTEx), Kaplan-Meier plotter, cBioPortal, STRING, GeneMANIA, and TISIDB were used to analyze the differential expression, prognostic value, gene changes, molecular interaction, and immune infiltration of KLKs in patients with KIRC.
From the gene expression level, it can be determined that KLK1, KLK6, and KLK7 are differentially expressed in KIRC and normal tissues. From the perspective of clinical prognosis, KLK1, KLK13, and KLK14 are highly correlated with the clinical prognosis of KIRC. The expression of KLKs is regulated by various immunosuppressive agents, with KDR, PVRL2, and VTCN1 being the most significant. The expression of KLKs is significantly correlated with the infiltration of various immune cells, of which Eosinophils and Neutrophils are the most significant.
KLK1, KLK6, KLK7, KLK13, and KLK14 have potential as diagnostic and prognostic biomarkers, among which KLK1 is the most significant. This study may provide detailed immune information and promising targets for KIRC immunotherapy to assist in designing new immunotherapies.
激肽释放酶（KLKs）已被证明是肿瘤微环境的关键调节因子。在本研究中，我们探讨了激肽释放酶相关肽酶（KLKs）作为肾透明细胞癌（KIRC）患者临床诊断和预后标志物的潜力，以及它们与肿瘤微环境中常见免疫抑制剂和免疫细胞浸润的关系，为KIRC治疗提供新的靶点和新思路。
使用Oncomine、基因表达谱交互式分析（GEPIA）、UCSC Xena、基因型-组织表达（GTEx）、Kaplan-Meier绘图仪、cBioPortal、STRING、GeneMANIA和TISIDB分析KLKs在KIRC患者中的差异表达、预后价值、基因变化、分子相互作用和免疫浸润。
从基因表达水平可以确定，KLK1、KLK6和KLK7在KIRC组织和正常组织中差异表达。从临床预后角度来看，KLK1、KLK13和KLK14与KIRC的临床预后高度相关。KLKs的表达受多种免疫抑制剂调节，其中KDR、PVRL2和VTCN1最为显著。KLKs的表达与多种免疫细胞的浸润显著相关，其中嗜酸性粒细胞和中性粒细胞最为显著。
KLK1、KLK6、KLK7、KLK13和KLK14有作为诊断和预后生物标志物的潜力，其中KLK1最为显著。本研究可能为KIRC免疫治疗提供详细的免疫信息和有前景的靶点，以协助设计新的免疫疗法。
